Heparin and Suramin Alter Plitidepsin Uptake Via Inhibition of GPCR Coupled Signaling

Abstract

Plitidepsin (Aplidin^®) is a novel antitumor agent, derived from the mediterranean tunicate Aplidium albicans, and is currently in phase II clinical trials with evidence of activity in heavily pretreated multiple myeloma, renal cell carcinoma, melanoma and neuroblastoma patients. As compared to its parental compound didemnin B, plitidepsin has shown a better therapeutic index with less bone marrow toxicity, cardiotoxicity and neurotoxicity in patients and a more potent cytotoxic effect in several tumor celllines. As sensitivity to the drug varies between cell lines and fresh leukemia samples, we performed studies on transport of plitidepsin in leukemia and lymphoma cell lines to determine the mechanism of uptake. The drug is taken up by an active transport process, i.e. The process is temperature and energy dependent, and has a high-affinity binding site with Kt = 212nM and Vmax = 15 pmoles/min. Importantly, once inside the cell, efflux of plitidepsin is minimum, suggesting that the drug is bound to intracellular macromolecules. Further work showed that plitidepsin binds to G-protein Coupled Receptors (GPCRs), since GPCR and GRK (GPCR kinases) inhibitors suramin and heparin respectively, markedly reduce the drug uptake and its cytotoxic activity. Signaling via Jak/Stat pathway is inhibited by pharmacological concentrations of plitidepsin, further confirming the relationship between plitidepsin and GPCRs.

Keywords:

• Plitidepsin
• Aplidium albicans
• multiple myeloma
• renal cell carcinoma
• melanoma
• neuroblastoma
• leukemia
• lymphoma
• suramin
• heparin